Vistagen Therapeutics
VTGN· Manufacturing· Fiscal year ends in March
CEO pay in FY2025Stock -52.7% in FY2025
Shawn K. Singh, J.D. is the CEO of Vistagen Therapeutics and was paid $2.5M in FY2025 (Mar), up 161%.
Pay$100 in the stock at the end of FY21 → $4
Executives4
See all- 1Shawn K. Singh, J.D.President, Chief Executive Officer and DirectorFY2025
- 2Reid G. Adler, J.D.Chief Legal OfficerFY2025
- 3Cynthia L. Anderson, CPAChief Financial Officer and TreasurerFY2025
- 4Joshua S. Prince, MBAChief Operating OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allVistagen Therapeutics paid its 4 named executives $5.8M in total in FY2025 (Mar). CEO Shawn K. Singh, J.D. was paid $2.5M of that.
| Name | |||
|---|---|---|---|
| Shawn K. Singh, J.D.President, Chief Executive Officer and Director | |||
| Reid G. Adler, J.D.Chief Legal Officer | |||
| Cynthia L. Anderson, CPAChief Financial Officer and Treasurer | Not disclosed | ||
| Joshua S. Prince, MBAChief Operating Officer |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Vistagen Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board1
See all- Ann M. CunninghamDirector · 4 yr on the boardNot independent—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Jul 28, 2025 | FY2025 |
| Annual report | 10-K | Jun 17, 2025 | FY2025 |
| Annual report | 10-K | Jun 11, 2024 | FY2024 |
| Proxy statement | DEF 14A | Apr 16, 2024 | FY2024 |
| Proxy statement | DEF 14A | Jul 28, 2023 | FY2023 |
| Annual report | 10-K | Jun 28, 2023 | FY2023 |
